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A
number of landmark randomized
clinical trials established that insu-
lin therapy reduces microvascular
complications (1,2). In addition, recent
follow-up data from the U.K. Prospective
Diabetes Study (UKPDS) suggest that
early insulin treatment also lowers mac-
rovascular risk in type 2 diabetes (3).
Whereas there is consensus on the need
for insulin, controversy exists on how to
initiate and intensify insulin therapy. The
options for the practical implementation
of insulin therapy are many. In this pre-
sentation, we will give an overview of the
evidence on the various insulin regimens
commonly used to treat type 2 diabetes.
Secondary analyses of the aforemen-
tioned landmark trials endeavored to es-
tablish a glycemic threshold value below
which no complications would occur.
The UKPDS found no evidence for such a
threshold for A1C, but instead showed
that better glycemic control was associ-
ated with reduced risks of complications
overthewholeglycemicrange(“thelower
the better”) (4). For the management of
type 2 diabetes, this resulted in the rec-
ommendation to “maintain glycemic lev-
els as close to the nondiabetic range as
possible” (5). However, in contrast to the
UKPDS, the Kumamoto study observed a
threshold,withnoexacerbationofmicro-
vascular complications in patients with
type 2 diabetes whose A1C was 6.5%,
suggesting no additional beneﬁt in lower-
ing A1C below this level (2). Moreover,
the intensive glycemia treatment arm of
theActiontoControlCardiovascularRisk
in Diabetes (ACCORD) study, targeting
A1C 6.0%, was discontinued because
of higher mortality in this group com-
pared with the standard therapy group
targeting A1C from 7.0 to 7.9% (6).
Therefore, the American Diabetes Associ-
ation (ADA) recommendation of an A1C
target 7.0% seems the most balanced
compromise at present (7).
Another important conclusion of the
UKPDS was that the risk reductions in
long-term complications were related to
the levels of glycemic control achieved,
rather than to a speciﬁc glucose-lowering
agent(1).Thishaslefthealthcareprovid-
ers and patients with the difﬁcult task of
choosing from the wide variety of glu-
cose-lowering interventions currently
available.Whenconsideringtheeffective-
ness, tolerability, and cost of the various
diabetes treatments, insulin is not only
the most potent, but also the most cost-
effective intervention (8). Although insu-
linhasnoupperdoselimitandnumerous
trials established that glycemic goals
could be attained by using adequate insu-
lin doses (5,8), in clinical practice, many
patients have elevated A1C levels and ex-
perience years of uncontrolled hypergly-
cemia (9). Moreover, the Steno-2 Study
demonstrated that only a minority of pa-
tients reached the intensive A1C target of
6.5%, compared with a far greater per-
centage of patients who reached the re-
spective intensive treatment goals for
blood pressure and serum lipid levels
(10).Apparently,theinitiationandinten-
siﬁcation of insulin therapy is not as
straightforward and simple as we had
hoped. In accordance with the ADA and
the European Association for the Study of
Diabetes(EASD)(5,7),weadvocateanal-
gorithmic approach for the start and ad-
justment of insulin treatment, with
modiﬁcations for individual patients as
needed.Thisreviewcontainsanoverview
of the currently available insulin prepara-
tions and an outline of the merits and dis-
advantages of the various regimens
commonly used for the initiation and in-
tensiﬁcation of insulin therapy in patients
with type 2 diabetes. Our aim is to assist
clinicians in designing individualized
management plans for insulin therapy in
type 2 diabetic patients.
HUMAN INSULIN AND ITS
ANALOGS— Insulin therapy with
the conventional mealtime and basal in-
sulin preparations has many shortcom-
ings. First, the absorption of regular
humaninsulinfromthesubcutaneoustis-
sueisslow,andthemetabolicactiontakes
effect only 30–60 min after injection and
peaks after 2–3 h. Consequently, treat-
ment with regular insulin is associated
with postmeal hyperglycemia and an in-
creased risk of late-postprandial hypogly-
cemia. Second, the conventional basal
NPH insulin has a distinct peak glucose-
lowering effect, has a duration of action
considerably shorter than 24 h, and is ab-
sorbed from the subcutaneous tissue at
variable rates. These pharmacodynamic
limitations predispose users to elevated
glucose levels before breakfast and noc-
turnal hypoglycemia (11,12). To over-
come these difﬁculties, insulin analogs
with a modiﬁed amino acid sequence
from the human insulin molecule were
developed. The three rapid-acting ana-
logs (aspart, glulisine, lispro) are ab-
sorbed more quickly than regular insulin
because of reduced self-association. Their
onset of action is within 15 min after sub-
cutaneous injection, and they have a
faster and greater peak action. Insulin
glargine, the ﬁrst long-acting insulin ana-
log to reach the market, was initially pro-
claimed to have the ideal “peakless,”
nearly24-hdurationofaction(13).How-
ever, these initial pharmacodynamic
studies raised some criticism, and it
should be concluded that there is no such
thing as a “peakless” insulin preparation
(12,14,15). Nevertheless, both long-
acting insulin analogs (detemir and
glargine) have a limited peak effect and a
longer mean duration of action compared
with NPH insulin (with glargine having a
slightly longer action than detemir
[13,16,17]).
It was expected that the rapid-acting
and long-acting analogs, which more
closely approximate physiological insulin
secretion, would confer important clini-
cal beneﬁts (11). With respect to type 2
diabetes, the topic of this review, it is im-
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type 2 diabetes have residual endogenous
insulin secretion in the context of insulin
resistance.Therefore,therationaleforim-
itating the insulin secretion pattern of hu-
man physiology is less convincing than in
type 1 diabetes. Indeed, in patients with
type 2 diabetes, the rapid-acting analogs
were not found to be superior to regular
insulin in reducing A1C levels or rates of
overall hypoglycemia (18). The clinical
beneﬁts of the long-acting insulin analogs
comparedwithNPHinsulinarelimitedto
a reduction in (nocturnal) hypoglycemia
(19).
WHEN SHOULD INSULIN
THERAPY BE INITIATED?— Type
2 diabetes is a progressive disease, and
thus,ultimatelythisquestionwillarisefor
many of our patients. Unfortunately,
there is no unequivocal answer, which
was nicely illustrated by a recent interac-
tive case vignette. The polling results
demonstrated once again that the man-
agement of patients with type 2 diabetes
uncontrolled by two oral glucose-
lowering agents is controversial. Further-
more, the preferred treatment option was
found to be related to the respondents’
locations and self-reported specialties
(20).
Traditionally, there has been a step-
wise introduction of glucose-lowering in-
terventions,withtheﬁnal“step”ofinsulin
therapy being administered 10–15 years
afterdiagnosis(8).Bothpatientsandphy-
sicians are often reluctant to start insulin
because of fears of painful injections, hy-
poglycemia,andweightgain(21,22).Ad-
ditionalreasonsfor“psychologicalinsulin
resistance” among patients are negative
beliefs about insulin treatment perma-
nence, restrictiveness, low self-efﬁcacy,
personal failure, and illness severity (22).
Drawbackofthestepwiseapproachisthat
the introduction of successive interven-
tions after treatment failure is often de-
layed, exposing patients to many years of
uncontrolled hyperglycemia (9). Another
reason for a more rapid response to treat-
ment failure is that lowering glycemia has
been shown to improve insulin resistance
as well as endogenous insulin secretion
(23). This was recently conﬁrmed by
Weng et al. (24) who found that a brief
course of insulin therapy in subjects with
newly diagnosed type 2 diabetes not only
restored, but also maintained, -cell
function, resulting in prolonged glycemic
remission. Interestingly, remission rates
were signiﬁcantly higher in the intensive
insulin groups than in the intensive oral
therapygroup.However,Weng’sﬁndings
needtobeconﬁrmed,andalsoforreasons
of practicality and patients’ acceptance,
we advocate stepwise diabetes treatment,
providedthat“anA1Cof7.0%servesas
a call to action to initiate or change ther-
apy” (5). Moreover, the response to this
call should be swift; given the great (cost-)
effectiveness, we advocate the initiation of
insulin when glycemic goals are not at-
tained after 2–3 months of maximally
dosed dual oral therapy. For patients in-
tolerant to one or more oral glucose-
lowering agents and who do not achieve
glycemic control with oral monotherapy,
as well as those with a personal prefer-
ence, earlier initiation of insulin is indi-
cated.Itisnoteworthythatrapidaddition
ofinsulintherapyissupportedbynumer-
ous studies showing improved treatment
satisfaction and quality-of-life for type 2
diabetic patients who had started using
insulin (25,26).
HOW SHOULD INSULIN
THERAPY BE INITIATED?
Basal insulin
The “treat-to-target” clinical trials estab-
lished that the addition of basal insulin to
existing oral glucose-lowering therapy
achievesgoodglycemiccontrolinthema-
jority of patients with type 2 diabetes
(27–29). According to the ADA/EASD al-
gorithm for the management of type 2 di-
abetes, insulin could be initiated with
either once-daily NPH insulin or a long-
acting insulin analog (5). For several rea-
sons, we consider NPH insulin the
preferred option. As previously men-
tioned, the relative beneﬁt of the long-
acting insulin analogs is limited to a
reduction in (nocturnal) hypoglycemia
(19). Moreover, this advantage is relevant
to only a minority, since most patients
with type 2 diabetes starting insulin ther-
apydonotexperiencehypoglycemiaatall
(12).Arecentmeta-analysisthatincluded
six randomized comparisons of NPH and
glargine found event rates for self-
monitoringofbloodglucose(SMBG)con-
ﬁrmed symptomatic hypoglycemia 65
mg/dl of only 138 and 91 events per 100
patient-years for these insulins, respec-
tively, in insulin-naive type 2 diabetic pa-
tients who achieved an A1C of 7.0% (30).
Finally, in this era of relentlessly increas-
ing incidence rates for type 2 diabetes,
physicians cannot afford to disregard the
elevated cost of the newer insulin prepa-
rations. In the U.S., the average retail
price of a 10-ml vial of the long-acting
insulin analogs is $105 compared with
$53 for a vial of NPH insulin (31). In this
respect, clinicians should realize that
when they stop prescribing conventional
insulin preparations, with established
beneﬁcial effects, they provide a pretext
for the manufacturers to withdraw these
drugs from the market. Recent examples
ofsuchindustryresponsestolowdemand
are the withdrawal of Novolin R penﬁlls
in the U.K. and of Novolin 70/30 in sev-
eralEuropeancountries.Thus,torecapit-
ulate, given its cost-effectiveness, we
consider NPH insulin the preferred agent
fortheinitiationofinsulintherapyintype
2 diabetes. However, if dose titration is
limited by (nocturnal) hypoglycemia, a
switch to a long-acting insulin analog
should be tried.
There is doubt as to whether a once-
daily dose of insulin detemir will help as
many people achieve good control as
NPH insulin and glargine. In a “treat-to-
target” trial with twice-daily detemir ad-
ministration, an end point A1C of 6.8%
was reached (28). In other studies, a sec-
ond daily detemir injection was required
in 34–55% of study subjects because of
predinner hyperglycemia or nocturnal
hypoglycemia (29,32). In the only re-
ported trial that investigated the efﬁcacy
of once-daily insulin detemir, A1C re-
mained above the currently recom-
mended glycemic goal with an end point
level of 7.4%, both for NPH insulin and
detemir (33), compared with an end of
study A1C 7.0% with once-daily
glargineandNPHintheoriginalTreat-to-
Target Trial (27). Rather than possible in-
sufﬁciency of a once-daily dose of insulin
detemir, these discrepant outcomes are
likelytobeexplainedbydiversityinstudy
design, such as different titration targets
andtitrationfrequency.Thisissupported
by Figs. 1A and B, which show the rela-
tionship between the reduction in A1C
level and end point insulin dose, and be-
tween A1C reduction and the frequency
of patient contact, respectively, in nine
randomized trials investigating insulin
initiation with basal insulin (27–29,32–
37). Both graphs show clear dose-
response relationships, suggesting that
substantial decreases in A1C can be
achieved, provided that the daily insulin
dose and the contact frequency are ade-
quate. The only way to ﬁnally determine
whether once-daily detemir injection is
appropriate for the treatment of type 2
diabetes is to conduct a clinical trial, ide-
ally comparing once-daily detemir and
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els of 8.5%. Such a study could also
assesswhetherhigherdetemirdosagesare
needed to obtain the same level of glyce-
mic control as with insulin glargine, as
wasdemonstratedintwooftheaforemen-
tioned studies in which detemir was ad-
ministered twice daily (28,29,38). This
trial could also conﬁrm the proclaimed
reduction in weight gain associated with
insulin detemir.
Titration and timing of basal insulin
After the recent unexpected ﬁnding of in-
creased mortality in the intensive glucose-
lowering therapy group of the ACCORD
study, which might be partly related to the
rate of the reduction in A1C (6), clinicians
maynowbemorereservedtolowerglucose
levels promptly. However, we still feel that
in addition to timely initiation, rapid titra-
tionofthedoseisindispensableforsuccess-
ful insulin therapy. The ACCORD study
solely included patients at high risk for car-
diovascular disease, in whom low A1C lev-
els were reached by using up to four or ﬁve
different classes of glucose-lowering drugs.
In contrast, in less selected patients treated
with stable doses of one or two oral agents,
simple titration algorithms targeting fasting
plasmaglucose100mg/dl(5.6mmol/l)
can safely achieve A1C of 7.0% (27). A pa-
tient-driven algorithm, with patients in-
creasing their insulin dose by 2 or 3 units
every 3 days, as long as their fasting plasma
glucose remains above target, constitutes a
practical approach that has been shown to
beequallyormoreeffectivethanphysician-
led titration (39,40).
Regarding the timing of injection in
once-daily basal insulin regimens, adminis-
tration of NPH in the evening appears to be
superior to morning injection (11,25).
Studies examining the injection time of the
long-acting insulin analogs showed con-
ﬂicting results. One study conducted with
insulin glargine found greater reductions in
A1C and nocturnal hypoglycemia with
morning compared with evening injection
(35),whereasalargercomparisonofmorn-
ing versus evening glargine with an identi-
cal study design did not ﬁnd any difference
(both studies investigated this issue against
a background of glimepiride once daily)
(41). A morning administration of insulin
detemir was associated with lower glucose
levels during the day and a trend toward a
reduced risk of nocturnal hypoglycemia
compared with evening injection (33).
From these discrepant data, it can be con-
cluded that when nocturnal hypoglycemia
limits dose titration of evening detemir or
glargine, administration in the morning
could be attempted.
Other options for the initiation of
insulin therapy
The recent Treating to Target in type 2
Diabetes (4-T) study compared the intro-
Figure 1—Relationships between mean end point daily insulin dose
(A) and the frequency of patient contact (clinical visits and telephone
contacts combined) (B) and mean reduction in A1C, and between mean
end point daily insulin dose and mean weight gain (C), during nine
randomized trials investigating insulin initiation with NPH insulin,
insulin detemir, or insulin glargine. Included studies are Bretzel et al.
(34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32),
Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29),
Yki-Ja ¨rvinen et al. (36), and Yki-Ja ¨rvinen et al. (37) (A and C). B does
notincludeHolman,sincethispublicationdidnotspecifythenumberof
interim telephone contacts. Two trials (28,35) did not report mean end
pointdailyinsulindoseasunitsperkilogramperday.Wecalculatedthe
desired ﬁgures from the mean end point dose reported as units per day
and mean body weight at study end. Three studies (Riddle and the two
studiesofYki-Ja ¨rvinen[27,36,37])didnotreportreductioninA1C.We
calculated these values from mean baseline and end point A1C levels.
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sulin initiation with either biphasic
insulin twice daily or prandial insulin be-
fore meals (32). The biphasic and pran-
dial insulin regimens provided better
glycemiccontrolthanonce-dailybasalin-
sulin (escalated to twice daily in 34% of
patients) but at the expense of increased
risks of hypoglycemia and weight gain.
Although biphasic insulin reduced A1C
levels to the same extent as prandial insu-
lin,thelatterregimenwasassociatedwith
the most hypoglycemic episodes and the
highest weight gain (32). Therefore, and
consideringthattodatethereisnoclinical
trialevidencesupportingthespeciﬁclow-
ering of postprandial glucose levels when
aiming to lower cardiovascular risk in
type 2 diabetes, initiation with prandial
insulin is generally not a ﬁrst-choice ap-
proach when starting insulin in type 2 di-
abetic patients. This was conﬁrmed by a
recently reported direct comparison of
once-daily insulin glargine versus thrice-
daily insulin lispro in insulin-naive pa-
tients (34). Finally, also regarding
feasibilityinclinicalpracticeandpatients’
acceptance, three injections per day is the
least attractive option for initiation of in-
sulin therapy.
Although many are accustomed to
initiationwithbiphasicinsulin,wegener-
ally recommend the addition of once-
daily basal insulin to oral therapy for
several reasons. First, the lower A1C lev-
elsreachedwithbiphasicinsulincomesat
the expense of increased risks of hypogly-
cemia and weight gain (32,42,43). Sec-
ond, and as aforementioned, trials with
systematic dose titration demonstrated
that once-daily basal insulin achieves the
currently recommended glycemic levels
in many patients with type 2 diabetes
(27,29). In this respect, it has frequently
been argued that in patients with badly
controlled hyperglycemia (e.g., A1C
8.5% at the start of insulin therapy),
treatment with once-daily basal insulin
alone would not attain glycemic goals
(11,32,33).However,theLANMETstudy
proved otherwise. In this clinical trial,
A1C levels decreased from 9.1% at base-
line to 7.1% with combination therapy of
bedtime insulin glargine or NPH insulin
and metformin (36). Finally, it seems
likely that insulin initiation by means of
one (basal) injection may also facilitate
patients’ acceptance of insulin initiation.
Combined therapy with oral agents
As discussed at the ﬁrst Controversies in
Obesity, Diabetes and Hypertension
(CODHy) meeting, the rationale for com-
bining insulin with oral therapy is mini-
mization of the adverse effects of insulin
treatment, i.e., hypoglycemia and weight
gain (44). Combination of insulin with
metformin is indeed associated with bet-
ter glycemic control, fewer hypoglycemic
events, and less weight gain than treat-
ment with insulin alone (45). Therefore,
metforminshouldbecontinuedwhenpa-
tientsareinitiatedoninsulintherapy(i.e.,
providing there are no intolerable side ef-
fects). Data concerning the combination
of insulin with either sulfonylureas alone,
or with both metformin and sulfonyl-
ureas, compared with insulin-alone treat-
ment regimens, are ambiguous (46). The
only consistent advantage of such com-
bined therapy is reduced insulin dose re-
quirements,whichmayresultinlessdaily
injections, easier dose titration, and im-
proved compliance (46). However, these
potential beneﬁts must be balanced
against the side effects and higher cost of
continuing sulfonylureas together with
metformincomparedwithtreatmentwith
metformin and NPH insulin alone—
although not versus long-acting insulin
analogs and metformin alone (31,46)—
and the possibility of reduced patient ad-
herence when increasing numbers of pills
are prescribed (47). An ongoing random-
ized trial comparing the continuation of
sulfonylureas in combination with met-
formin and insulin glargine versus dis-
continuation of sulfonylureas with this
combination regimen in insulin-naive
type 2 diabetic patients will hopefully
providefurtherevidenceregardingthisis-
sue (ISRCTN29335793: www.controlled-
trials.com).
INTENSIFICATION OF
INSULIN THERAPY
When should insulin therapy be
intensiﬁed?
Because of progressive -cell decline,
treatment with once-daily basal insulin
alone will eventually fail to maintain gly-
cemic control in a substantial number of
patients with type 2 diabetes. When the
recommended A1C level of 7.0% is not
reached, or maintained despite successful
basal insulin dose titration maintaining
fasting plasma glucose 100 mg/dl, or
whenaggressivetitrationislimitedbyhy-
poglycemia, treatment should be intensi-
ﬁed by adding insulin injections.
How should insulin therapy be
intensiﬁed?
The available options for additional insu-
lininjectionsincludeasecondinjectionof
basal insulin, prandial insulin before one
or more meals, or a switch to biphasic
insulin. The choice between intensiﬁca-
tion of basal insulin versus the introduc-
tionofprandialorbiphasicinsulinshould
be individualized based on patients’ diur-
nal blood glucose proﬁles. When consid-
ering the proﬁles obtained with NPH
insulin or long-acting insulin analog once
daily, the effect appears to wane during
the day, even in patients starting insulin
therapy, i.e., with remaining endogenous
insulin secretion (33,37,48). These pa-
tients could beneﬁt from adding a second
injection of basal insulin (48). However,
in the context of declining endogenous
insulin secretion, daytime hyperglycemia
is usually related to elevated postprandial
glucose levels, favoring the initiation of
prandial or biphasic insulin.
Tworecentstudiesestablishedthatin
patients not achieving adequate glycemic
controlwithonce-dailybasalinsulin,bas-
al-bolustherapyresultsingreaterA1Cre-
ductions than biphasic insulin twice or
thrice daily (49,50). However, when a
more gradual intensiﬁcation of insulin
treatment is preferred, patients can be
switched to biphasic insulin two, and
subsequentlythree,timesdaily.Thelatter
regimen has been shown to signiﬁcantly
improveA1Clevelsofpatientspreviously
treated with insulin glargine (50).
Whether stepwise introduction of meal-
time injections is as safe and effective as
the rapid initiation of a full basal-bolus
regimen is currently under investigation
(51).
Finally, regarding the choice of pran-
dial insulin, rapid-acting insulin analogs
are not superior to regular insulin in re-
ducing A1C levels or rates for overall and
nocturnal hypoglycemia, despite improv-
ing postprandial control (18). In some
studies, treatment with rapid-acting ana-
logs was associated with fewer severe hy-
poglycemic episodes and improved
treatment satisfaction (18), the latter
probably being related to increased con-
venience because of injection immedi-
ately before meals. In conclusion, there is
nocompellingreasontooverallfavorrap-
id-acting insulin analogs over regular in-
sulin in type 2 diabetes. Whereas in some
countriesthepriceofrapid-actinganalogs
has been lowered to the level of regular
insulin,inothers,itremainsaroundtwice
as high (31).
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infusion
In patients with type 2 diabetes already
using at least one daily insulin injection,
the introduction of intensive insulin ther-
apy with continuous subcutaneous insu-
lin infusion resulted in comparable
glycemic control, weight gain, and hypo-
glycemia risk as multiple daily injection
therapy (52,53). Although continuous
subcutaneous insulin infusion was asso-
ciatedwithgreaterimprovementsintreat-
ment satisfaction in one study (53), we
recommend that its use be restricted to
selected patients in experienced centers
only.
DRAWBACKS OF INSULIN
THERAPY
Hypoglycemia
Intensive glucose-lowering therapy inev-
itably results in an increased rate of
hypoglycemia,whichwasonceagaincon-
ﬁrmed in the recent ACCORD study with
annualized rates of hypoglycemic epi-
sodes requiring medical assistance of 3.1
and 1.0% in the intensive and standard
therapy groups, respectively (6). Iatro-
genic hypoglycemia hampers tight glyce-
miccontrolandisconsideredthelimiting
factor in diabetes management (54).
Opinions are divided on the extent of
the problem, with cited event rates for se-
vere hypoglycemia in insulin-treated type
2 diabetic patients ranging from between
1 and 3 (5) to between 10 and 73 per 100
patient-years (55). Of note, the relatively
low rates were found in clinical trials
(2,56), whereas the higher ﬁgures were
reported in retrospective and population-
based studies (57–59). The difference is
probably explained by varying durations
of disease or insulin therapy in the cited
studies. The risks of mild and severe hy-
poglycemiaarelowamongtype2diabetic
patients just beginning insulin therapy
(30) and appear to increase with increas-
ing durations of diabetes and insulin
treatment (57–59).
To conclude, in type 2 diabetes, the
frequency of hypoglycemia is generally
lower than that in type 1 diabetes (54).
This is presumably the result of relative
protection of type 2 diabetic patients
against hypoglycemia by residual endog-
enous (i.e., physiologically regulated) in-
sulin and glucagon secretion, insulin
resistance, and higher glycemic thresh-
olds for counterregulatory and symptom-
atic responses to hypoglycemia (60,61).
Therefore, when initiating insulin ther-
apy, attempts to attain A1C goals should
not be hampered too much by concerns
abouthypoglycemia.However,iatrogenic
hypoglycemia appears to become a more
frequent problem at the insulin-deﬁcient
stage of the disease, warranting more vig-
ilance as the disease advances (54).
Weight gain
The 2- to 4-kg increase in body weight
associated with insulin therapy has tradi-
tionally been explained by reductions of
glucosuria and resting energy expendi-
ture when glycemic control is improved
(5,46). Other explanations are snacking
to prevent, or in response to, hypoglyce-
mia or restoration of the weight loss usu-
ally preceding insulin initiation to the
weight before onset of diabetes. In con-
trast, a recent study found that the mean
weightgainof1.8kgin23type2diabetic
patientsduringtheﬁrst6monthsofinsu-
lin therapy was not accompanied by a
change in glucosuria, resting energy ex-
penditure, or physical activity. The au-
thors concluded that increased energy
intake was the only plausible explanation
for the observed weight increments (62).
Although the mechanisms underlying in-
sulin-associated weight gain are still not
fully understood, it is thought to be pro-
portional to the number of insulin injec-
tions, or the total daily insulin dose
(32,45,46). Interestingly, when consider-
ing studies investigating basal insulin ini-
tiation in type 2 diabetes, we found no
evidence for such a dose-response rela-
tionship (Fig. 1C).
Finally, when directly comparing the
mean increases in body weight during in-
sulin initiation with NPH insulin versus
long-acting insulin analogs, insulin
glargine is associated with similar weight
gain (27,35–37). Treatment with insulin
detemir, on the other hand, appears to
result in less weight gain than NPH insu-
lin (28,33). However, considering the
limitedmagnitudeofthereportedweight-
sparing effect, we still recommend NPH
insulinfortheinitiationofinsulintherapy
in patients with type 2 diabetes.
CONCLUSIONS— Although insu-
lin has no upper dose limit and numer-
ous trials established that glycemic
goals can be attained by using adequate
doses, in clinical practice, many pa-
tients experience years of uncontrolled
hyperglycemia.
Because most type 2 diabetic patients
have residual endogenous insulin secre-
tion, the rationale for imitating the phys-
iological insulin secretion pattern is less
convincing than in type 1 diabetes.
Glycemic treatment should be step-
wise with swift introduction of successive
interventions after treatment failure (i.e.,
A1C 7.0%). Insulin should be initiated
when A1C is 7.0% after 2–3 months of
dual oral therapy. The preferred regimen
for insulin initiation in type 2 diabetes is
once-daily basal insulin. In addition to
timely initiation, rapid titration of the
dose is indispensable for successful insu-
lintherapy.Hypoglycemiariskisverylow
among type 2 diabetic patients just start-
ing insulin therapy, making NPH insulin
the most cost-effective drug.
When glycemic goals are not attained
despite successful basal insulin dose titra-
tion (i.e., fasting plasma glucose 100
mg/dl), or when titration is limited by hy-
poglycemia, treatment should be intensi-
ﬁed by addition of prandial or biphasic
insulin.
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